Skip to main content

Table 4 G-CSF usage at the first course of MVAC chemotherapy

From: Co-administration of dexamethasone increases severity and accelerates onset day of neutropenia in bladder cancer patients on methotrexate, vinblastine, adriamycin and cisplatin chemotherapy: a retrospective cohort study

  Dex (−) (n = 6) Dex 1 day (n = 12) Dex multiday (n = 6)
G-CSF use (%) 50 75 100
P value   0.34 0.18
Day of Onset of first G-CSF use 18.0 ± 2.0 15.1 ± 2.7 13.7 ± 1.5
P value   0.17 0.04
  1. P values are for G-CSF use with Dex 1 day and multiday versus Dex (−), as determined by Fisher’s exact test
  2. Onset day of G-CSF first use data are mean ± SD. P values are for onset day of G-CSF use with Dex (1 day or multiday) versus Dex (−), as determined by ANOVA with post hoc Tukey’s test